Personal information

Pheochromocytoma, Neuroblastoma, catecholamine, metanephrine, somatostatine, theranostics, biochemical diagnosis
Switzerland

Activities

Employment (4)

Université de Lausanne: Lausanne, CH

2022-05 to present | Expert scientifique/head of the laboratory (dpt de médecine de laboratoire et de pathologie, Service de pharmacologie clinique)
Employment
Source: Self-asserted source
Karim Alexandre Abid

Université de Lausanne: Lausanne, CH

2006-09 to 2022-05 | Responsable de recherche (dpt de médecine de laboratoire et de pathologie, Service de pharmacologie clinique)
Employment
Source: Self-asserted source
Karim Alexandre Abid

University of Texas Medical Branch: Galveston, TX, US

2004-01-01 to 2005-12-30 | Postdoc fellow (Neurology)
Employment
Source: Self-asserted source
Karim Alexandre Abid

Université de Genève: Genève, CH

1998-09 to 2003-12 | PhD Student (Médecine interne, Service de Gastroentérologie)
Employment
Source: Self-asserted source
Karim Alexandre Abid

Education and qualifications (3)

Université de Lausanne: Lausanne, CH

Maitre d'enseignement et de recherche clinique (dpt de médecine de laboratoire et de pathologie)
Education
Source: Self-asserted source
Karim Alexandre Abid

Université de Genève: Genève, CH

1998-09 to 2003-12 | PhD (Médecine Interne, Service de Gastro-entérologie)
Education
Source: Self-asserted source
Karim Alexandre Abid

Université de Genève: Geneva, CH

1996-09 to 1998-03 | Master (Médecine Génétique)
Education
Source: Self-asserted source
Karim Alexandre Abid

Funding (6)

Preclinical model to improve 131I-mIBG uptake as a therapeutic modality in neuroblastoma

2025-03 to 2026-09 | Grant
Zoé4Life foundation (Lausanne, CH)
Source: Self-asserted source
Karim Alexandre Abid

Proof of concept of therapeutic application of 131MIBG in the neuroblastoma IGR-NB8 xenograft mouse model with a dual histone deacetylase and PI3K inhibitor

2022-06 to 2022-12 | Grant
PACCT-Technology Transfer Unit (Lausanne, CH)
Source: Self-asserted source
Karim Alexandre Abid

Grant No. 44222.1 IP-LS: Epigenetic regulation to improve imaging and therapy of neuroendocrine tumors with ST8950 a new SSTR/SSTR5 agonist

2021 to 2023 | Grant
Innosuisse - Schweizerische Agentur für Innovationsförderung (Bern, CH)
Source: Self-asserted source
Karim Alexandre Abid

Grant no 310030-176162/1: Enhancing monoamine transporters expression in neuroendocrine tumors to improve radionuclide imaging and therapy

2018-03 to 2021-09 | Grant
Swiss National Science Foundation (Bern, CH)
Source: Self-asserted source
Karim Alexandre Abid

Grant for young researcher PBGE33-104766, Prion Biology

2004-01 to 2005-12 | Grant
Swiss National Science Foundation (Bern, CH)
Source: Self-asserted source
Karim Alexandre Abid

Hepatitis C biology

1999 to 2000 | Grant
cancer et solidarité (Geneva, CH)
Source: Self-asserted source
Karim Alexandre Abid